Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN).

Giulio Francolini,Angelo Porreca,Gaetano Facchini,Daniele Santini,Alessio Bruni,Nicola Simoni,Marco Trovò,Mattia Falchetto Osti,Giuseppe Fornarini,Michele Sisani,Vanessa Di Cataldo,Beatrice Detti,Pietro Garlatti,Niccolò Bertini,Luca Burchini,Giulio Frosini,Ilaria Bonaparte,Sergio Serni,Andrea Minervini,Lorenzo Livi

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.tps235

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:TPS235 Background: TITAN trial showed that apalutamide + ADT improved OS in patients with metastatic hormone sensitive prostate cancer (mHSPC), both in low and high-volume disease. On the other hand, SABR-COMET trial suggested that stereotactic body radiotherapy (SBRT) improved outcomes in oligometastatic patients if compared to systemic therapy alone. Recently, one trial suggested that SBRT may offer significant benefit in terms of biochemical response and progression free survival within oligometastatic castrate resistant prostate cancer patients undergoing first line abiraterone acetate treatment (ARTO trial, NCT03449719). However, there are no data specifically assessing the benefit offered by SBRT in oligometastatic mHSPC treated with apalutamide. PERSIAN trial is aimed to test the hypothesis that metastases directed SBRT will improve outcomes in select subgroups of pts with oligometastatic mHSPC treated with apalutamide + ADT. Moreover, we implemented baseline blood sample tests at enrollment/randomization, to evaluate the status of PIK3CA/AKT1/PTEN and BRCA1/BRCA2 mutations, and to investigate the predictive value of these alterations on treatment response. Furthermore, oncometabolites expression will be evaluated through metabolomic analysis before and after start of SBRT. Methods: PERSIAN trial is a prospective phase II randomized superiority study. All patients are affected by metachronous oligometastatic HSPC defined as presence of < 5 non-visceral metastatic lesions. Patients with de novo metastatic disease are excluded from the trial. Patients will be randomized to receive standard systemic treatment alone with apalutamide + ADT (Arm A: Control) or the same systemic treatment combined with SBRT on all sites of metastatic spread (Arm B: Treatment). This trial design will allow us to evaluate the benefit of SBRT in a selected cohort of patients with identical systemic treatments. Primary endpoint of the trial is the rate of patients with complete biochemical response (PSA < 0.2 ng/ml) 6 months after apalutamide + ADT start. Assuming a rate of complete biochemical response of 61% in the control arm, a sample size of 180 patients will have 80% statistical power to detect an absolute benefit of 19% in the treatment group, with alpha 0.05. Secondary endpoints are: time to PSA progression, radiologic progression free survival, frequency of treatment severe adverse events, overall and cancer specific survival, quality of life (measured with EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires). Enrollment started in March 2023, 31 patients have been enrolled to date. Clinical trial information: NCT05717660 .

oncology